Cytoseek Limited

CytoSeek's mission is to use Artificial Membrane Binding Protein technology to deliver the potential of the next generation of cell therapies, with a focus on treating solid tumours. 

The company was founded in November 2017 to commercialise the technology developed by Professor Adam Perriman and his team at the University of Bristol.

CytoSeek is now engaged in proof of principle studies for multiple product candidates, and is seeking to enhance cell therapies against solid tumours.

Twitter Account
@CYTOSEEK